16:43 , Sep 21, 2018 |  BC Week In Review  |  Clinical News

Eureka's ET140202 leads to tumor regression in Phase I for HCC

Eureka Therapeutics Inc. (Emeryville, Calif.) said ET140202 led to one case of complete tumor regression and two cases of partial tumor regression in six evaluable patients with alpha fetoprotein (AFP)-positive hepatocellular carcinoma (HCC) in a...
23:35 , Aug 22, 2018 |  BC Innovations  |  Translation in Brief

Confirming CRISPR

Two critiques of a 2017 human embryo gene editing study, including one suggesting large deletions at the target site misled researchers into thinking CRISPR-Cas9 corrected a genetic mutation, raise questions about what assays and screening...
21:30 , Jul 24, 2018 |  BC Innovations  |  Translation in Brief

Interaction analysis

In a collaboration with Merck & Co. Inc. (NYSE:MRK) and SomaLogic Inc., University of Cambridge researchers have identified associations and causal relationships between thousands of genetic variants, plasma proteins and disease states, which could reveal...
17:50 , Jul 20, 2018 |  BC Week In Review  |  Company News

PTC acquiring CNS gene therapy play Agilis

PTC Therapeutics Inc. (NASDAQ:PTCT) will acquire gene therapy company Agilis Biotherapeutics Inc. (Cambridge, Mass.), giving the rare disease company four products in development for CNS disorders. PTC will pay Agilis shareholders about $200 million up...
22:43 , Jul 19, 2018 |  BC Extra  |  Company News

PTC acquiring CNS gene therapy play Agilis

PTC Therapeutics Inc. (NASDAQ:PTCT) will acquire gene therapy company Agilis Biotherapeutics Inc. (Cambridge, Mass.), giving the rare disease company four products in development for CNS disorders. PTC will pay Agilis shareholders about $200 million up...
15:41 , Jul 18, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling Mutations in hematopoiesis-associated genes could help predict the risk of AML. Genomic sequencing of 124 patients who later developed AML and 686 healthy volunteers identified associations between the disease and mutations in...
21:40 , Jul 10, 2018 |  BC Extra  |  Preclinical News

Models could help predict AML risk

In a...
00:43 , Jun 29, 2018 |  BC Innovations  |  Product R&D

Highly personal

Pact Pharma Inc. has raised $120 million in venture financing to tackle one of the most complex forms of personalized medicine proposed to date: neoantigen-targeted T cells. Backed by Alphabet Inc.’s GV, the company is...
21:36 , May 30, 2018 |  BC Extra  |  Preclinical News

Tet2 disruption improves Kymriah efficacy

In a...
18:54 , May 10, 2018 |  BC Innovations  |  Strategy

Finding phenotype

NIH wants to find direct relationships between genes and disease more efficiently than GWAS or other standard approaches allow. The institute has teamed up with Inova Health System to create a searchable pool of genomes...